Effect of cyclophosphamide in active nonviral cirrhosis
Szanto, P.; Stanciu, L.; Togănel, E.; Dejica, D.
Romanian Journal of Internal Medicine 29(3-4): 205-210
1991
ISSN/ISBN: 1220-4749 PMID: 1784950 Document Number: 386165
The immunologic effects of cyclophosphamide were studied in 16 patients with active nonviral liver cirrhosis with a view to improving the pathogenic treatment of these diseases. After months of cyclophosphamide administration first in doses of 100 mg/day (for 14 days) then in doses of 200 mg per week, the hypergammaglobulinemia present at entry was reduced significantly from 2.55 .+-. 0.35 g/dl to 1.71 .+-. 0.17 g/dl concomitantly with the proportional increase of the active suppressor T lymphocytes, from 29.3 .+-. 3.59% to 38.0 .+-. 2.1%. The use of smaller doses of cyclophosphamide, i.e., 200 mg/week, allowed the maintenance of its immunosuppressive properties and prevented its side effects.